U.S. Bioscience
Executive Summary
Licenses worldwide rights to oral chemoprotective agent WR151327 from the Southern Research Institute (SRI) of Birmingham, Alabama. Clinical trials for the drug are expected to begin in 1989. Kodak subsidiary Sterling has a sublicense to develop the product in Europe as part of an overall agreement involving three other anticancer agents. WR151327 is related to another product licensed by U.S. Bio-science from SRI, Ethyol. That drug is currently in Phase III study....